Cleveland Alzheimer's Disease Research Center

总体来说 项目总结 克利夫兰阿尔茨海默病研究中心(CADRC)是 来自凯斯西储大学(CWRU)、克利夫兰临床基金会的医生和研究人员 (CCF)、地铁卫生系统(MHS)、大学医院(UH)和路易斯托克斯克利夫兰退伍军人管理局 建立一个由国家老龄研究所(NIA)资助的阿尔茨海默病研究中心。这个 CADRC将代表一个丰富的临床和研究社区，以及大约22万名遭受痛苦的俄亥俄州人 来自阿尔茨海默病(AD)。目前，俄亥俄州没有阿尔茨海默病研究中心。 CADRC将汇集医学界和学术界的大量专业知识 在俄亥俄州东北部，关注我们国家面临的最大的医疗保健危机之一。CADRC将专注于 阿尔茨海默病和阿尔茨海默病相关痴呆的临床和病理异质性研究 (ADRD)。 CADRC将建立一个基础设施，以帮助加快地方、国家和 国际调查人员。CADRC将参与国家阿尔茨海默氏症中心计划，并 当来自全国各地的中心合作时，为可能的“大科学”做出贡献。我们将招募受试者 由于独特的地区人口或研究(痴呆症)，俄亥俄州东北部处于很好的研究位置的样本 路易小体和快速进展性阿尔茨海默病被国家Prion病病理监测确定 中心)或与我们对AD和相关痴呆的理解相关(认知正常的老年人，AD 和轻度认知障碍)。我们将通过添加生物流体来增加这些受试者样本的评估价值 收集和分析以及尖端图像。还将特别重视少数族裔的入学 人口往往没有得到很好的研究。 我们对那些已经表现出的合作精神感到鼓舞。 来自CWRU、CCF、MHS、UH和LSVA的CADRC规划，以及我们从 俄亥俄州东北部社区。我们相信，这对俄亥俄州来说是一个很好的机会，可以为 阿尔茨海默病研究中心计划并改进对这些毁灭性疾病的治疗 精神错乱。

OVERALL PROJECT SUMMARY The Cleveland Alzheimer’s Disease Research Center (CADRC) is a collaborative effort amongst physicians and investigators from Case Western Reserve University (CWRU), the Cleveland Clinic Foundation (CCF), the Metro Health System (MHS), University Hospitals (UH), and the Louis Stokes Cleveland VA Medical Center (LSVA), to establish a National Institute on Aging (NIA) funded Alzheimer’s disease research center. The CADRC would represent a rich clinical and research community and an estimated 220,000 Ohioans who suffer from Alzheimer’s disease (AD). Currently there is no Alzheimer’s Disease Research Center in Ohio. The CADRC will bring together the considerable expertise from the medical and academic communities in northeast Ohio to focus on one of the largest health care crises facing our country. The CADRC will be focused on the increasingly recognized clinical and pathologic heterogeneity observed in AD and AD-Related Dementias (ADRD). The CADRC will create an infrastructure to help speed up the research efforts of local, national and international investigators. The CADRC will participate in the national Alzheimer’s Centers program and contribute to the “big science” possible when centers from around the country collaborate. We will recruit subject samples that northeast Ohio is well situated to study due to unique regional populations or studies (dementia with Lewy bodies and rapidly progressive AD identified by the National Prion Disease Pathology Surveillance Center,) or relevant to our understanding of AD and related dementias (cognitively normal older individuals, AD and mild cognitive impairment). We will add value to the evaluation of these subject samples by adding biofluid collection and analysis and cutting edge imaging. Special emphasis will also be placed on enrollment of minority populations not often well-studied. We are quite encouraged by the collaborative spirit already demonstrated by those participating in the CADRC planning from CWRU, CCF, MHS, UH, and LSVA and from the support we have received from the northeast Ohio community. We believe this is a great opportunity for Ohio to contribute to the greater efforts of the Alzheimer’s Disease Research Centers program and to improve the treatments for these devastating disorders.